Postmastectomy hypofractionated and accelerated radiation therapy with (and Without) subcutaneous amifostine cytoprotection

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 1, 2013, Pages e7-

  Koukourakis, Michael I ^a   Panteliadou, Marianthi ^a   Abatzoglou, Ioannis M ^a   Sismanidou, Kyriaki ^a   Sivridis, Efthimios ^a   Giatromanolaki, Alexandra ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS;

DISEASE-SPECIFIC SURVIVALS; HIGH-RISK PATIENTS; HUMAN EPIDERMAL GROWTH FACTOR; HYPOFRACTIONATED; METHODS AND MATERIALS; POSTMASTECTOMY RADIATION THERAPIES; RADIOGRAPHIC FINDINGS; STEROID RECEPTORS;

RADIOTHERAPY;

AMIFOSTINE; GAMMA UROGASTRONE; HUMAN EPIDERMAL GROWTH FACTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CELL PROTECTION; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEVER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INTERSTITIAL PNEUMONIA; LOCAL RECURRENCE FREE SURVIVAL; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RASH; SCAR; SKIN EXFOLIATION; SKIN PROTECTION; TRIPLE NEGATIVE BREAST CANCER; VOMITING;

EID: 84871384685     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.08.017     Document Type: Article

References (17)

1. M.E. Taylor, B.G. Haffty, and R. Rabinovitch ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast Int J Radiat Oncol Biol Phys 73 2009 997 1002
2. N.P. Rowell Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: a systematic review Radiother Oncol 91 2009 23 32
3. M. Overgaard, H.M. Nielsen, and J. Overgaard Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 B&C randomized trials Radiother Oncol 82 2007 247 253 (Pubitemid 46350797)
4. M. Clarke, R. Collins, and S. Darby Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 2005 2087 2106 (Pubitemid 41797643)
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) S. Darby, P. McGale, and C. Correa Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials Lancet 378 2011 1707 1716
6. M. Kyndi, F.B. Sorensen, and H. Knudsen Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group J Clin Oncol 26 2008 1419 1426
7. M.I. Koukourakis, A. Giatromanolaki, and C. Kouroussis Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients Int J Radiat Oncol Biol Phys 52 2002 144 155 (Pubitemid 34044112)
8. M.I. Koukourakis, P.G. Tsoutsou, and I.M. Abatzoglou Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report Int J Radiat Oncol Biol Phys 74 2009 1173 1180
9. START Trialists' Group S.M. Bentzen, R.K. Agrawal, and E.G. Aird The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial Lancet Oncol 9 2008 331 341
10. www.accessdata.fda.gov/scripts/cder/onctools/toxcrit2.cfm.
11. [No authors listed] LENT SOMA tables Radiother Oncol 35 1995 17 60
12. B. Macejewski, J.M. Taylor, and H.R. Wither Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx Radiother Oncol 7 1986 323 326 (Pubitemid 17232171)
13. S.L. Wang, Y.X. Li, and Y.W. Song Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy Int J Radiat Oncol Biol Phys 80 2011 1095 1101
14. B.S. Abdulkarim, J. Cuartero, and J. Hanson Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy J Clin Oncol 29 2011 2852 2858
15. D.J. Brennan, K. Jirstrom, and A. Kronblad CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance Clin Cancer Res 12 2006 6421 6431 (Pubitemid 44799714)
16. P. Manders, F.C. Sweep, and V.C. Tjan-Heijnen Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients Clin Cancer Res 9 2003 6363 6370 (Pubitemid 38031821)
17. H. Bartelink, J.C. Horiot, and P.M. Poortmans Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial J Clin Oncol 25 2007 3259 3265 (Pubitemid 47325610)